Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Horizon Discovery Group bids farewell to Abcam founder who exits board following failed bid approach

Jonathan Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"
boardroom table
Will Horizon look to fill the vacant non-executive director position or leave the seat vacant

It was all very cordial, but there was an air of inevitability about the departure of Dr Jonathan Milner from the board of gene editing specialist Horizon Discovery Group PLC (LON:HZD).

For those unaware of the background, Abcam PLC (LON:ABC), the company founded by Milner, recently launched an unwelcome £270mln bid for Horizon that ultimately failed.

Milner's exit ends a decade-long association with Horizon and he wished the team there well, adding he felt "enormously privileged to have been a part of this exciting journey"

Enthusiastic about the future 

"I continue to be encouraged and enthusiastic about the growth prospects of Horizon's business, and intend to remain a shareholder for the foreseeable future," he went on.

Horizon chairman Dr Ian Gilham for his part said he was sorry to see Milner depart, but understood the decision to prioritise "other commitments"

"We are extremely grateful for his valuable insights as a member of Horizon's board over many years and wish him well in his future, not least as a considerable founding shareholder of the Horizon business."

 

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

researcher filling a vial
May 29 2018
ImmuPharma chairman Tim McCarthy said: "We continue to believe Lupuzor has the potential to bring a much needed treatment to Lupus sufferers around the world"
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
researcher filling a vial
July 16 2018
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use